BC Platforms, known for its healthcare data and analytics systems, snapped up Scandinavian CRO 4Pharma, which has dual headquarters in Sweden and Finland, as part of a move to expand its services.
Although financial details of the sale weren’t disclosed, the deal is expected to be completed by the end of the second quarter, the company said in a June 1 press release.
As part of the agreement, 4Pharma CEO Tero Oinonen will become BCP’s executive vice president for North-Europe.
With the purchase, BCP gets 4Pharma’s medical research services that include solutions for the management and delivery of clinical trial data, patient safety data collection, analysis and reporting, and support for global regulatory submissions to the FDA, European Medicines Agency and Japan’s Pharmaceuticals and Medical Devices Agency.
“This expands our service offering to healthcare and life sciences customers, as well as connecting data partners in a global, interoperable federated network,” Tero Silvola, BCP’s chief executive, said in the release. “We combine omics (studies involving genomics, proteomics, phenomics, etc.) and clinical data assets around the world, without compromising data privacy and security.”
Switzerland-based BCP is focused on using machine learning and AI to generate clinical, and drug development, insights from real-world data.
The company closed on a $20 million financing round in November that it is using to expand its footprint in Europe and Asia. That round was led by Jolt Capital, which is headquartered in Paris.